Data as of Dec 19
| -0.30 / -3.93%|
The 6 analysts offering 12-month price forecasts for Conatus Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 19.00 and a low estimate of 13.00. The median estimate represents a +118.28% increase from the last price of 7.33.
The current consensus among 5 polled investment analysts is to Buy stock in Conatus Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.